A citation-based method for searching scientific literature

Diego A Pizzagalli, Moria Smoski, Yuen-Siang Ang, Alexis E Whitton, Gerard Sanacora, Sanjay J Mathew, John Nurnberger, Sarah H Lisanby, Dan V Iosifescu, James W Murrough, Hongqiu Yang, Richard D Weiner, Joseph R Calabrese, Wayne Goodman, William Z Potter, Andrew D Krystal. Neuropsychopharmacology 2020
Times Cited: 11







List of co-cited articles
65 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia.
Andrew D Krystal, Diego A Pizzagalli, Moria Smoski, Sanjay J Mathew, John Nurnberger, Sarah H Lisanby, Dan Iosifescu, James W Murrough, Hongqiu Yang, Richard D Weiner,[...]. Nat Med 2020
47
72

Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase.
Michael R Bruchas, Tao Yang, Selena Schreiber, Mia Defino, Steven C Kwan, Shuang Li, Charles Chavkin. J Biol Chem 2007
132
36

Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.
William A Carlezon, Andrew D Krystal. Depress Anxiety 2016
72
36


Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects.
Stephen L Lowe, Conrad J Wong, Jennifer Witcher, Celedon R Gonzales, Gemma L Dickinson, Robert L Bell, Linda Rorick-Kehn, MaryAnn Weller, Randall R Stoltz, Jane Royalty,[...]. J Clin Pharmacol 2014
56
27

Receptor Occupancy of the κ-Opioid Antagonist LY2456302 Measured with Positron Emission Tomography and the Novel Radiotracer 11C-LY2795050.
Mika Naganawa, Gemma L Dickinson, Ming-Qiang Zheng, Shannan Henry, Francois Vandenhende, Jennifer Witcher, Robert Bell, Nabeel Nabulsi, Shu-Fei Lin, Jim Ropchan,[...]. J Pharmacol Exp Ther 2016
33
27

A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of JDTic.
Jeffrey J Buda, F I Carroll, Thomas R Kosten, Dennis Swearingen, Bradford B Walters. Neuropsychopharmacology 2015
31
27

Development of κ opioid receptor antagonists.
F Ivy Carroll, William A Carlezon. J Med Chem 2013
105
27


Neurocircuitry of addiction.
George F Koob, Nora D Volkow. Neuropsychopharmacology 2010
27


Time-dependent neuronal changes associated with craving in opioid dependence: an fMRI study.
Anna Murphy, Dan I Lubman, Shane McKie, Prun S Bijral, Lesley A Peters, Qasim Faiz, Sophie E Holmes, Ian M Anderson, Bill Deakin, Rebecca Elliott. Addict Biol 2018
17
27

Neurobiology of addiction: a neurocircuitry analysis.
George F Koob, Nora D Volkow. Lancet Psychiatry 2016
27

Kappa Opioid Receptor Antagonists as Potential Therapeutics for Stress-Related Disorders.
Moriah L Jacobson, Caroline A Browne, Irwin Lucki. Annu Rev Pharmacol Toxicol 2020
17
18

Preclinical evaluation of the kappa-opioid receptor antagonist CERC-501 as a candidate therapeutic for alcohol use disorders.
E Domi, E Barbier, E Augier, G Augier, D Gehlert, R Barchiesi, A Thorsell, L Holm, M Heilig. Neuropsychopharmacology 2018
29
18

Identification of short-acting κ-opioid receptor antagonists with anxiolytic-like activity.
Matthew F Peters, Anna Zacco, John Gordon, Carla M Maciag, Linda C Litwin, Carolann Thompson, Patricia Schroeder, Linda A Sygowski, Timothy M Piser, Todd A Brugel. Eur J Pharmacol 2011
39
18

Chromatin alterations in response to forced swimming underlie increased prodynorphin transcription.
B Reed, N Fang, B Mayer-Blackwell, S Chen, V Yuferov, Y Zhou, M J Kreek. Neuroscience 2012
27
18


Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats.
Stephen D Mague, Andrea M Pliakas, Mark S Todtenkopf, Hilarie C Tomasiewicz, Yan Zhang, William C Stevens, Robert M Jones, Philip S Portoghese, William A Carlezon. J Pharmacol Exp Ther 2003
373
18

Evaluation of the agonist PET radioligand [¹¹C]GR103545 to image kappa opioid receptor in humans: kinetic model selection, test-retest reproducibility and receptor occupancy by the antagonist PF-04455242.
Mika Naganawa, Leslie K Jacobsen, Ming-Qiang Zheng, Shu-Fei Lin, Anindita Banerjee, Wonkyung Byon, David Weinzimmer, Giampaolo Tomasi, Nabeel Nabulsi, Sarah Grimwood,[...]. Neuroimage 2014
36
18

Duration of action of a broad range of selective κ-opioid receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation.
Erica J Melief, Mayumi Miyatake, F Ivy Carroll, Cécile Béguin, William A Carlezon, Bruce M Cohen, Sarah Grimwood, Charles H Mitch, Linda Rorick-Kehn, Charles Chavkin. Mol Pharmacol 2011
80
18

Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence.
Brian Reed, Eduardo R Butelman, Rebecca S Fry, Rachel Kimani, Mary Jeanne Kreek. Neuropsychopharmacology 2018
33
18

Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity.
Thomas A Munro, Loren M Berry, Ashlee Van't Veer, Cécile Béguin, F Ivy Carroll, Zhiyang Zhao, William A Carlezon, Bruce M Cohen. BMC Pharmacol 2012
61
18

Adolescent forced swim stress increases social anxiety-like behaviors and alters kappa opioid receptor function in the basolateral amygdala of male rats.
E I Varlinskaya, J M Johnson, K R Przybysz, T Deak, M R Diaz. Prog Neuropsychopharmacol Biol Psychiatry 2020
9
22

Sex Differences in the Effects of a Kappa Opioid Receptor Antagonist in the Forced Swim Test.
Abigail Laman-Maharg, Alexia V Williams, Mikaela D Zufelt, Vanessa A Minie, Stephanie Ramos-Maciel, Rebecca Hao, Evelyn Ordoñes Sanchez, Tiffany Copeland, Jill L Silverman, Angelina Leigh,[...]. Front Pharmacol 2018
23
18

LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders.
Linda M Rorick-Kehn, Jeffrey M Witkin, Michael A Statnick, Elizabeth L Eberle, Jamie H McKinzie, Steven D Kahl, Beth M Forster, Conrad J Wong, Xia Li, Robert S Crile,[...]. Neuropharmacology 2014
88
18

Factors modulating neural reactivity to drug cues in addiction: a survey of human neuroimaging studies.
Agnes J Jasinska, Elliot A Stein, Jochen Kaiser, Marcus J Naumer, Yavor Yalachkov. Neurosci Biobehav Rev 2014
275
18


The neural basis of drug stimulus processing and craving: an activation likelihood estimation meta-analysis.
Henry W Chase, Simon B Eickhoff, Angela R Laird, Lee Hogarth. Biol Psychiatry 2011
192
18

Neural substrates of cue reactivity: association with treatment outcomes and relapse.
Kelly E Courtney, Joseph P Schacht, Kent Hutchison, Daniel J O Roche, Lara A Ray. Addict Biol 2016
111
18

The clinical neurobiology of drug craving.
Rajita Sinha. Curr Opin Neurobiol 2013
82
18

The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system.
Benjamin B Land, Michael R Bruchas, Julia C Lemos, Mei Xu, Erica J Melief, Charles Chavkin. J Neurosci 2008
397
18

Deficits in autonomic indices of emotion regulation and reward processing associated with prescription opioid use and misuse.
Eric L Garland, Craig J Bryan, Yoshio Nakamura, Brett Froeliger, Matthew O Howard. Psychopharmacology (Berl) 2017
41
18

Pleasure systems in the brain.
Kent C Berridge, Morten L Kringelbach. Neuron 2015
526
18

Distinct opioid circuits determine the palatability and the desirability of rewarding events.
K M Wassum, S B Ostlund, N T Maidment, B W Balleine. Proc Natl Acad Sci U S A 2009
113
18

The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development.
Andrew D Krystal, Diego A Pizzagalli, Sanjay J Mathew, Gerard Sanacora, Richard Keefe, Allen Song, Joseph Calabrese, Andrew Goddard, Wayne Goodman, Sarah H Lisanby,[...]. Nat Rev Drug Discov 2018
27
18

Acute effect of methadone maintenance dose on brain FMRI response to heroin-related cues.
Daniel D Langleben, Kosha Ruparel, Igor Elman, Samantha Busch-Winokur, Ramapriyan Pratiwadi, James Loughead, Charles P O'Brien, Anna R Childress. Am J Psychiatry 2008
128
18

Can neuroimaging help combat the opioid epidemic? A systematic review of clinical and pharmacological challenge fMRI studies with recommendations for future research.
Hestia Moningka, Sarah Lichenstein, Patrick D Worhunsky, Elise E DeVito, Dustin Scheinost, Sarah W Yip. Neuropsychopharmacology 2019
24
18

Neurokinin 1 receptor antagonism as a possible therapy for alcoholism.
David T George, Jodi Gilman, Jacqueline Hersh, Annika Thorsell, David Herion, Christopher Geyer, Xiaomei Peng, William Kielbasa, Robert Rawlings, John E Brandt,[...]. Science 2008
164
18

Psychotomimesis mediated by kappa opiate receptors.
A Pfeiffer, V Brantl, A Herz, H M Emrich. Science 1986
655
18

Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial.
Maurizio Fava, Asli Memisoglu, Michael E Thase, J Alexander Bodkin, Madhukar H Trivedi, Marc de Somer, Yangchun Du, Richard Leigh-Pemberton, Lauren DiPetrillo, Bernard Silverman,[...]. Am J Psychiatry 2016
100
18

Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats.
Allison T Knoll, Edward G Meloni, James B Thomas, F Ivy Carroll, William A Carlezon. J Pharmacol Exp Ther 2007
183
18

Activation of CREB in the nucleus accumbens shell produces anhedonia and resistance to extinction of fear in rats.
John W Muschamp, Ashlee Van't Veer, Aram Parsegian, Miranda S Gallo, Melissa Chen, Rachael L Neve, Edward G Meloni, William A Carlezon. J Neurosci 2011
78
18

Dynorphin, Dysphoria, and Dependence: the Stress of Addiction.
Charles Chavkin, George F Koob. Neuropsychopharmacology 2016
81
18

Endogenous kappa opioid activation mediates stress-induced deficits in learning and memory.
Amanda N Carey, Angela M Lyons, Christopher F Shay, Ocean Dunton, Jay P McLaughlin. J Neurosci 2009
68
18


Sex-dependent neurobiological features of prenatal immune activation via TLR7.
Galen Missig, James O Robbins, Emery L Mokler, Kenneth M McCullough, Staci D Bilbo, Christopher J McDougle, William A Carlezon. Mol Psychiatry 2020
19
18

Maternal and Early Postnatal Immune Activation Produce Dissociable Effects on Neurotransmission in mPFC-Amygdala Circuits.
Yan Li, Galen Missig, Beate C Finger, Samantha M Landino, Abigail J Alexander, Emery L Mokler, James O Robbins, Yunona Manasian, Woori Kim, Kwang-Soo Kim,[...]. J Neurosci 2018
34
18

Effects of Chronic Social Defeat Stress on Sleep and Circadian Rhythms Are Mitigated by Kappa-Opioid Receptor Antagonism.
Audrey M Wells, Elysia Ridener, Clinton A Bourbonais, Woori Kim, Harry Pantazopoulos, F Ivy Carroll, Kwang-Soo Kim, Bruce M Cohen, William A Carlezon. J Neurosci 2017
46
18

Pathway- and Cell-Specific Kappa-Opioid Receptor Modulation of Excitation-Inhibition Balance Differentially Gates D1 and D2 Accumbens Neuron Activity.
Hugo A Tejeda, Jocelyn Wu, Alana R Kornspun, Marco Pignatelli, Vadim Kashtelyan, Michael J Krashes, Brad B Lowell, William A Carlezon, Antonello Bonci. Neuron 2017
75
18


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.